Research programme: G protein-coupled receptor modulators - Actelion Pharmaceuticals
Alternative Names: GPCR modulators - ActelionLatest Information Update: 27 Jun 2017
At a glance
- Originator Actelion Pharmaceuticals
- Class
- Mechanism of Action G protein-coupled receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cardiovascular disorders
Most Recent Events
- 16 Jun 2017 Actelion Pharmaceuticals was acquired by Janssen Pharmaceuticals
- 12 Jun 2007 Discontinued - Preclinical for Cardiovascular disorders in Switzerland (unspecified route)
- 19 Nov 2003 Axovan has been acquired by Actelion Pharmaceuticals